Compare CDMOs with sterile injectable manufacturing capabilities. Filter by container type, aseptic technology, and regulatory approvals.
Sterile injectable manufacturing produces parenteral drug products -- formulations administered by injection (intravenous, subcutaneous, intramuscular, intrathecal). These products require the highest level of manufacturing control because they bypass the body's natural defense barriers. Any microbial, particulate, or endotoxin contamination can be life-threatening.
The sterile injectable market is growing faster than overall pharma, driven by biologics (monoclonal antibodies, ADCs), specialty injectables (long-acting formulations, complex generics), and the shift toward self-administered subcutaneous products. Capacity remains constrained globally, with lead times of 12-24 months at many CDMOs.
No companies found in this category yet. Check back soon.
Browse all CDMOsOur AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.